This clarifies that overexpressing HTRA1 in the retina is not a viable therapeutic approach and, instead, supports the therapeutic hypothesis that HTRA1 protease inhibition could be beneficial for patients with AMD. This evidence concerns the gene HTRA1 and age-related macular degeneration.